Table 1 Demographic and clinical characteristics of HIV infected adults experiencing virologic failure
Characteristics | Overall | Not switched | Switched |
|---|---|---|---|
n(%) | n(%) | n(%) | |
Population | 124 | 42(34%) | 82(66%) |
Age in years | |||
18–24 | 14(11%) | 3(7%) | 11(13%) |
25–34 | 66(53%) | 18(43%) | 48(59%) |
≥ 35 | 44(35%) | 21(50%) | 23(28%) |
Gender | |||
Female | 75(60%) | 23(55%) | 52(63%) |
Male | 49(40%) | 19(45%) | 30(37%) |
Year of ART Initiation | |||
2004–2007 | 78(63%) | 26(62%) | 52(63%) |
2008–2011 | 46(37%) | 16(38%) | 30(37%) |
Type of ART treatment Clinic | |||
Central Clinic | 23(19%) | 7(17%) | 16(20%) |
Peripheral clinic | 101(81%) | 35(83%) | 66(80%) |
WHO Stage | |||
1 | 34(27%) | 10(24%) | 24(29%) |
2 | 50(40%) | 17(40%) | 33(40%) |
3 or 4 | 40(32%) | 15(36%) | 25(30%) |
First Line ART regimen | |||
EFV based regimen | 36(29%) | 14(33%) | 22(27%) |
NVP based regimen | 88(71%) | 28(67%) | 60(73%) |
CD4 count at ART initiation (cells/ul) | |||
≥ 100 | 78(63%) | 33(79%) | 45(55%) |
≤ 99 | 46(37%) | 9(21%) | 37(45%) |
CD4 count at ART failure (cells/ul)a | |||
≥ 100 | 92(91%) | 32(94%) | 60(90%) |
≤ 99 | 9(9%) | 2(6%) | 7(10%) |
viral load at ART failure (cells/ul) | |||
≤ 5000 | 33(27%) | 18(43%) | 15(18%) |
5001–10,000 | 19(15%) | 6(14%) | 13(16%) |
> 10,000 | 72(58%) | 18(43%) | 54(66%) |
Year of virologic failure | |||
2005–2007 | 37(30%) | 11(26%) | 26(32%) |
2008–2013 | 87(70%) | 31(74%) | 56(68%) |
Virologic suppression prior to virologic failure | |||
No | 57(46%) | 17(40%) | 40(49%) |
Yes | 67(54%) | 25(60%) | 42(51%) |
Time from ART start to virologic failure | |||
0–12 months | 36(29%) | 14(33%) | 22(27%) |
13–24 months | 56(45%) | 14(33%) | 42(51%) |
25–36 months | 23(19%) | 8(19%) | 15(18%) |
≥ 37 months | 9(7%) | 6(14%) | 3(4%) |
Time from virologic failure to Switch (months) | |||
0–6 months | N/A | N/A | 36(44%) |
7–12 months | N/A | N/A | 16(20%) |
13–24 months | N/A | N/A | 19(23%) |
≥ 25 months | N/A | N/A | 11(13%) |